Reply to L. Dirix, B. De Laere et al, and A. Sharp et al.
暂无分享,去创建一个
H. Scher | E. Antonarakis | D. Nanus | S. Halabi | Andrew J. Armstrong | Jun Luo | Daniel J. George | Andrew J Armstrong
[1] A. Zoubeidi,et al. Biological Evolution of Castration-resistant Prostate Cancer. , 2019, European urology focus.
[2] Jun Luo,et al. Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma: Diagnostic and therapeutic implications , 2018, Asian journal of urology.
[3] M. Gleave,et al. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. , 2018, European urology.
[4] Sean R. Landman,et al. Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer , 2016, Nature Communications.
[5] David S. K. Lu,et al. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.
[6] Lawrence D. True,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.